2025
Clinical Implications of Breast Cancer Intrinsic Subtypes
Rios-Hoyo A, Shan N, Karn P, Pusztai L. Clinical Implications of Breast Cancer Intrinsic Subtypes. Advances In Experimental Medicine And Biology 2025, 1464: 435-448. PMID: 39821037, DOI: 10.1007/978-3-031-70875-6_21.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantFemaleGene Expression Regulation, NeoplasticHumansNeoplasm Recurrence, LocalPrognosisReceptors, EstrogenConceptsBasal-like cancersBreast cancerDistant recurrenceLuminal cancersEndocrine therapyAdjuvant chemotherapyClinical behaviorOncotype DX recurrence scorePathologic complete response rateTreated with preoperative chemotherapyExcellent long-term survivalRisk of early recurrenceBasal-like breast cancerBreast cancer intrinsic subtypesHER2-enriched cancersImmunotherapy to chemotherapyLuminal A cancersComplete response rateImmune checkpoint inhibitorsEstrogen receptor-negativeHER2-targeted therapyEstrogen receptor-positiveLevel of immune infiltrationHER2 gene amplificationAdjuvant endocrine therapyDermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.
Bordeaux J, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bolotin D, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, LeBoeuf N, Lukens J, Manber S, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Paragh G, Park S, Patel T, Rich J, Shaha A, Sharma B, Sokumbi Y, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. Journal Of The National Comprehensive Cancer Network 2025, 23 PMID: 39819674, DOI: 10.6004/jnccn.2025.0001.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyDermatofibrosarcomaHumansMedical OncologyNeoplasm Recurrence, LocalSkin NeoplasmsConceptsNCCN Clinical Practice GuidelinesDermatofibrosarcoma protuberansClinical practice guidelinesNegative marginsFibrosarcomatous dermatofibrosarcoma protuberansRate of recurrenceSoft tissue sarcomasRecommended treatment optionPractice guidelinesCutaneous soft tissue sarcomasLocal recurrenceRadiation therapySurgical excisionAggressive variantSystemic treatmentInitial treatmentTissue sarcomasTreatment optionsLocal infiltrationIncreased riskRecurrenceMetastasisProtuberansMultidisciplinary teamNCCNOutcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
DeMichele A, Dueck A, Hlauschek D, Martin M, Burstein H, Pfeiler G, Zdenkowski N, Wolff A, Bellet-Ezquerra M, Winer E, Balic M, Miller K, Colleoni M, Lake D, Rubovsky G, Cameron D, Balko J, Singer C, Nowecki Z, Iwata H, Wolmark N, Parraga K, Rugo H, Steger G, Traina T, Werutsky G, Czajkowska D, Metzger O, El-Abed S, Theall K, Lu R, O’Brien P, Fesl C, Mayer E, Gnant M. Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]). Breast Cancer Research 2025, 27: 12. PMID: 39849600, PMCID: PMC11761723, DOI: 10.1186/s13058-024-01941-3.Peer-Reviewed Original ResearchConceptsLocoregional relapse-free survivalStandard adjuvant endocrine therapyYears of palbociclibAdjuvant endocrine therapyEndocrine therapyOverall survivalStage IIAPALLAS trialBreast cancerFollow-upBreast cancer-free survivalReducing breast cancer recurrenceStage IIA patientsHigher stage diseaseHormone-receptor-positiveRelapse-free survivalStage IIA diseaseYears of follow-upCancer-free survivalMedian follow-upPhase III trialsEarly breast cancerBreast cancer recurrenceBreast Cancer Study GroupNegative breast cancer
2024
Quality of Cancer Recurrence Data in the National Cancer Database: A Reappraisal of Reporting Readiness
Chan K, Palis B, Cotler J, Janczewski L, Zhu X, Boffa D, Park K, Boughey J, Plichta J, In H, Nogueira L, Yabroff R, Hawhee V, Merriman K, Habermann E, Williams V, Mason K, Mullett T, Weigel R, Nelson H. Quality of Cancer Recurrence Data in the National Cancer Database: A Reappraisal of Reporting Readiness. Annals Of Surgical Oncology 2024, 32: 1553-1564. PMID: 39739153, DOI: 10.1245/s10434-024-16801-9.Peer-Reviewed Original ResearchMeSH KeywordsAgedData AccuracyDatabases, FactualFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasmsPrognosisRegistriesUnited StatesConceptsCancer registry staffData missingnessNational Cancer DatabaseSouthern geographic regionsMulti-method studyPhysician documentationStaff surveyData quality concernsRegistry staffNon-metastatic cancerClinical documentationOutcomes researchData abstractionInadequate documentationCancer DatabasePrimary cancerOverall low rateCancer recurrenceBackgroundThis studyNational Cancer Database analysisMissingnessRecurrence dataSurveyDocumentation of recurrenceGeographic regionsEfficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Foss F, Kim Y, Prince H, Akilov O, Querfeld C, Seminario-Vidal L, Fisher D, Kuzel T, Yannakou C, Geskin L, Feldman T, Sokol L, Allen P, Dang N, Cabanillas F, Wong H, Ooi C, Xing D, Sauter N, Singh P, Czuczman M, Duvic M. Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. Journal Of Clinical Oncology 2024, 43: 1198-1209. PMID: 39700456, PMCID: PMC11949209, DOI: 10.1200/jco-24-01549.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaTreatment-emergent adverse eventsTime to responseT-cell lymphomaTumor burdenRefractory cutaneous T-cell lymphomaEnd pointsEfficacy end pointCapillary leak syndromePrimary efficacy analysisSecondary end pointsHuman interleukin-2Unmet medical needMedian DoRSystemic therapyInfusion reactionsOpen-labelDenileukin diftitoxEfficacy analysisAdverse eventsInterleukin-2Safety resultsQ1-Q3PatientsResponse rateIdentification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial
Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, El-Abed S, Di Cosimo S, Ueno T, Izquierdo M, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C. Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial. Nature Communications 2024, 15: 10402. PMID: 39613746, PMCID: PMC11607438, DOI: 10.1038/s41467-024-54621-3.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, ImmunologicalBiomarkers, TumorBreast NeoplasmsClinical Trials, Phase III as TopicFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiddle AgedNeoplasm Recurrence, LocalPrognosisRandomized Controlled Trials as TopicReceptor, ErbB-2TrastuzumabTumor MicroenvironmentConceptsHER2-positive breast cancerMolecular subtypesBreast cancerRate of pathological complete responseSensitive to HER2-targeted therapiesClinical trialsRisk of distant recurrenceBreast cancer molecular subtypesPathological complete responseHER2-targeted therapyCancer molecular subtypesPotential clinical implicationsNeoALTTO trialDistant recurrenceComplete responseAdjuvant trastuzumabPrognostic/predictive valueHeterogeneous biologySurvival outcomesI-SPY2Clinical outcomesMicroenvironment featuresGene expression profilesExternal cohortTumorGrowth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy
Di Pastena F, Pond G, Tsakiridis E, Gouveia A, Ahmadi E, Biziotis O, Ali A, Swaminath A, Okawara G, Ellis P, Abdulkarim B, Ahmed N, Robinson A, Roa W, Valdes M, Kavsak P, Wierzbicki M, Wright J, Steinberg G, Tsakiridis T. Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy. Radiation Oncology 2024, 19: 155. PMID: 39511611, PMCID: PMC11542377, DOI: 10.1186/s13014-024-02546-y.Peer-Reviewed Original ResearchConceptsLocally advanced non-small cell lung cancerAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerOverall survivalDifferentiation factor 15GDF15 levelsLA-NSCLCTumor volumeSurvival outcomesUnresectable locally advanced non-small cell lung cancerLung cancerPhase II randomized clinical trialConcurrent chest radiotherapyIncreased GDF15 levelsUnresectable LA-NSCLCTreated with chemoradiotherapyGross target volumeGrowth differentiation factor 15Platinum-based chemotherapyPlasma GDF15 levelsRandomized to treatmentLevels of GDF15Patient blood plasmaRandomized clinical trialsLong-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, PMCID: PMC11581571, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchMeSH KeywordsAgedHumansMaleMiddle AgedNeoplasm Recurrence, LocalPositron-Emission TomographyProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease courseHypermethylated TAGMe as a universal-cancer-only methylation marker and its application in diagnosis and recurrence monitoring of urothelial carcinoma
Yang Z, Chen Q, Dong S, Xu P, Zheng W, Mao Z, Qian C, Zheng X, Dai L, Wang C, Shi H, Li J, Yuan J, Yu W, Xu C. Hypermethylated TAGMe as a universal-cancer-only methylation marker and its application in diagnosis and recurrence monitoring of urothelial carcinoma. Journal Of Translational Medicine 2024, 22: 608. PMID: 38956589, PMCID: PMC11218302, DOI: 10.1186/s12967-024-05420-3.Peer-Reviewed Original ResearchConceptsRecurrence monitoringMethodsThe methylation levelsIndicator of recurrenceBackgroundUrothelial carcinomaClinical recurrenceUrothelial carcinomaBenign diseaseUrological malignanciesPostoperative surveillanceUC diagnosisUC patientsTraining cohortUrothelial markersValidation cohortRecurrenceClinical scenariosUrinary systemClinical utilityCarcinomaMethylation markersPatientsUrine samplesTissue samplesUrineDiagnosisMulti-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers
Belmont E, Bansal V, Yousef M, Zeineddine M, Su D, Dhiman A, Liao C, Polite B, Eng O, Fournier K, White M, Turaga K, Shen J, Shergill A. Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers. JCO Precision Oncology 2024, 8: e2300531. PMID: 38723230, DOI: 10.1200/po.23.00531.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAppendiceal NeoplasmsCirculating Tumor DNAFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalConceptsCirculating tumor DNAComplete cytoreductive surgeryCirculating tumor DNA detectionAppendiceal cancerPeritoneal metastasisGrade 2Systemic therapyTumor DNAComplete CRSAssociated with shorter recurrence-free survivalCirculating tumor DNA testingShorter recurrence-free survivalSystemic therapy responseRecurrence-free survivalDiagnosis of recurrenceDetection of recurrenceMulti-institutional studyCytoreductive surgerySystemic chemotherapyCA19-9Elevated biomarkersTherapy responseCtDNA detectionSpecialized centersCarcinoembryonic antigenMultimodality Imaging of Postmastectomy Breast Reconstruction Techniques, Complications, and Tumor Recurrence.
Thai J, Sodagari F, Colwell A, Winograd J, Revzin M, Mahmoud H, Mozayan S, Chou S, Destounis S, Butler R. Multimodality Imaging of Postmastectomy Breast Reconstruction Techniques, Complications, and Tumor Recurrence. RadioGraphics 2024, 44: e230070. PMID: 38573814, DOI: 10.1148/rg.230070.Peer-Reviewed Original ResearchMeSH KeywordsBreast ImplantsBreast NeoplasmsFemaleHumansMammaplastyMastectomyNeoplasm Recurrence, LocalNipplesPostoperative ComplicationsRetrospective StudiesConceptsTumor recurrencePostoperative evaluation of patientsFlap reconstruction methodsImplant-based reconstructionMultimodal imagingBreast reconstruction techniquesFat graft placementBreast cancer recurrenceTissue flap reconstructionEvaluation of patientsNipple-sparing techniquesTissue donor sitesFlap-based reconstructionNipple-areolar complex reconstructionDiagnostic breast imagingUnique patient populationAutologous tissue flapsAbnormal imaging appearancesBreast cancer screeningMastectomy optionLocal recurrenceOncoplastic surgeryDisease recurrenceFlap reconstructionReconstructed breastDe-Escalated Therapy and Early Treatment of Recurrences in HPV-Associated Head and Neck Cancer: The Potential for Biomarkers to Revolutionize Personalized Therapy
Yarbrough W, Schrank T, Burtness B, Issaeva N. De-Escalated Therapy and Early Treatment of Recurrences in HPV-Associated Head and Neck Cancer: The Potential for Biomarkers to Revolutionize Personalized Therapy. Viruses 2024, 16: 536. PMID: 38675879, PMCID: PMC11053602, DOI: 10.3390/v16040536.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorHead and Neck NeoplasmsHumansNeoplasm Recurrence, LocalPapillomaviridaePapillomavirus InfectionsPrecision MedicineSquamous Cell Carcinoma of Head and NeckConceptsHPV+ HNSCCHPV-associated head and neck cancerHead and neck cancerHuman papillomavirus-associatedDe-escalation therapyDetect recurrent diseaseTreatment of recurrenceHPV-associated cancersHead and neckEarly treatment of recurrencePapillomavirus-associatedDevelopment of biomarkersResponsive tumorsRecurrent diseaseStandard therapyCompanion biomarkersHPV carcinogenesisHPV vaccinationNeck cancerPoor prognosisDecrease morbidityHNSCCEarly treatmentMolecular vulnerabilitiesPersonalized therapySomatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
Risueño A, See W, Bluemmert I, de Botton S, DiNardo C, Fathi A, Schuh A, Montesinos P, Vyas P, Prebet T, Gandhi A, Hasan M. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML. Leukemia Research 2024, 140: 107497. PMID: 38564986, DOI: 10.1016/j.leukres.2024.107497.Peer-Reviewed Original ResearchConceptsConventional care regimensMutational burdenR/R AMLCo-mutationsIDH2-R172Co-mutation patternsAssociated with decreased overall survivalRelapsed/refractory acute myeloid leukemiaTargeted next-generation sequencingAML patient cohortNewly diagnosed AMLLow mutational burdenEvent-free survivalLimited treatment optionsAcute myeloid leukemiaGene mutation patternsIDH2 variantsIDH2 R140Prognostic impactOverall survivalPrognostic relevanceSurvival benefitMyeloid leukemiaIDH2 mutationsPatient cohortAnalytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer
Marín-Aguilera M, Jares P, Sanfeliu E, Villacampa G, Hernández-lllán E, Martínez-Puchol A, Shankar S, González-Farré B, Waks A, Brasó-Maristany F, Pardo F, Manning D, Abery J, Curaba J, Moon L, Gordon O, Galván P, Wachirakantapong P, Castillo O, Nee C, Blasco P, Senevirathne T, Sirenko V, Martínez-Sáez O, Aguirre A, Krop I, Li Z, Spellman P, Filho O, Polyak K, Michaels P, Puig-Butillé J, Vivancos A, Matito J, Buckingham W, Perou C, Villagrasa-González P, Prat A, Parker J, Paré L. Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer. ESMO Open 2024, 9: 102903. PMID: 38452436, PMCID: PMC10937240, DOI: 10.1016/j.esmoop.2024.102903.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsFemaleHumansNeoplasm Recurrence, LocalReproducibility of ResultsRNARNA, MessengerConceptsEarly-stage HER2-positive breast cancerHER2-positive breast cancerTumor cell contentBreast cancerRecurrence riskEarly-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancerHuman epidermal growth factor receptor 2 (HER2)-positive breast cancerLow tumor cell contentBreast cancer recurrence riskERBB2 mRNA expressionFormalin-fixed paraffin-embedded (FFPE) tumor tissuesPost-neoadjuvant therapyCancer recurrence riskFFPE tumor samplesGenomic testingReagent lotsMessenger RNAProtocol variationsRNA extraction kitsFFPE tumorsHER2DXCell contentTumor samplesIntratumoral variabilityTumor tissuesTransplantation: platform to study recurrence of disease
Burke G, Mitrofanova A, Fontanella A, Vendrame F, Ciancio G, Vianna R, Roth D, Ruiz P, Abitbol C, Chandar J, Merscher S, Pugliese A, Fornoni A. Transplantation: platform to study recurrence of disease. Frontiers In Immunology 2024, 15: 1354101. PMID: 38495894, PMCID: PMC10940352, DOI: 10.3389/fimmu.2024.1354101.Peer-Reviewed Original ResearchMeSH KeywordsGlomerulosclerosis, Focal SegmentalHumansKidney Failure, ChronicKidney TransplantationNeoplasm Recurrence, LocalTransplantsPlasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma
Kim I, Diamond M, Yuan S, Kemp S, Kahn B, Li Q, Lin J, Li J, Norgard R, Thomas S, Merolle M, Katsuda T, Tobias J, Baslan T, Politi K, Vonderheide R, Stanger B. Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma. Nature Communications 2024, 15: 1532. PMID: 38378697, PMCID: PMC10879147, DOI: 10.1038/s41467-024-46048-7.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Pancreatic DuctalCell Line, TumorEpithelial-Mesenchymal TransitionHumansImmunotherapyNeoplasm Recurrence, LocalPancreatic NeoplasmsTumor MicroenvironmentConceptsPancreatic ductal adenocarcinomaEpithelial-to-mesenchymal transitionResistance to immunotherapyT cell killingDuctal adenocarcinomaAcquired resistance to immunotherapyResistance to cancer immunotherapyMouse model of pancreatic ductal adenocarcinomaModel of pancreatic ductal adenocarcinomaExpression of immune checkpointsInterferon regulatory factor 6Effect of TNF-aEMT transcription factor ZEB1Antigen presentation machineryTumor immune microenvironmentCell-intrinsic defectsPro-apoptotic effectsPresentation machineryCancer immunotherapyImmune checkpointsTumor relapseImmune microenvironmentPrimary resistanceT cellsAcquired resistanceSearching for the “Holy Grail” of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA)
Gao L, Medford A, Spring L, Bar Y, Hu B, Jimenez R, Isakoff S, Bardia A, Peppercorn J. Searching for the “Holy Grail” of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA). Breast Cancer Research And Treatment 2024, 205: 211-226. PMID: 38355821, DOI: 10.1007/s10549-024-07253-6.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsCirculating Tumor DNAFemaleHumansNeoplasm Recurrence, LocalNeoplasm, ResidualNeoplastic Cells, CirculatingPrognosisConceptsCirculating tumor DNABreast cancer careSystemic therapyTumor DNABreast cancerBreast cancer recurrence riskRisk of recurrenceCancer careCancer recurrence riskCirculating tumor cellsNarrative reviewTreat many patientsBreast cancer evaluationDistant diseaseFear of recurrenceBreast oncologistsPredictive biomarkersRecurrence riskTumor cellsCancer evaluationImprove prognosticationClinical challengeTreatment selectionPatientsBreastONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
Arrillaga-Romany I, Gardner S, Odia Y, Aguilera D, Allen J, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit K, Graber J, Haggiagi A, Harrison R, Kheradpour A, Kilburn L, Kurz S, Lu G, MacDonald T, Mehta M, Melemed A, Nghiemphu P, Ramage S, Shonka N, Sumrall A, Tarapore R, Taylor L, Umemura Y, Wen P. ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma. Journal Of Clinical Oncology 2024, 42: 1542-1552. PMID: 38335473, PMCID: PMC11095894, DOI: 10.1200/jco.23.01134.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBrain NeoplasmsChildChild, PreschoolFemaleGliomaHistonesHumansMaleMiddle AgedMutationNeoplasm Recurrence, LocalPyridonesPyrimidinesYoung AdultConceptsH3 K27M-mutant diffuse midline gliomaDiffuse midline gliomaDuration of responseTime to responseHigh-grade gliomasLow-grade gliomasMidline gliomaMedian duration of responseMedian time to responseTreatment-emergent adverse eventsEnd pointsBlinded independent central reviewCorticosteroid dose reductionIndependent central reviewSecondary end pointsClinically meaningful efficacyRadiographic end pointsSpinal tumorsDose reductionDismal prognosisCentral reviewPerformance scoresCorticosteroid responseResponse assessmentAdverse eventsIDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy
Tanner G, Barrow R, Ajaib S, Al-Jabri M, Ahmed N, Pollock S, Finetti M, Rippaus N, Bruns A, Syed K, Poulter J, Matthews L, Hughes T, Wilson E, Johnson C, Varn F, Brüning-Richardson A, Hogg C, Droop A, Gusnanto A, Care M, Cutillo L, Westhead D, Short S, Jenkinson M, Brodbelt A, Chakrabarty A, Ismail A, Verhaak R, Stead L. IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy. Genome Biology 2024, 25: 45. PMID: 38326875, PMCID: PMC10848526, DOI: 10.1186/s13059-024-03172-3.Peer-Reviewed Original ResearchMeSH KeywordsBrainBrain NeoplasmsDNA MethylationGene Expression Regulation, NeoplasticGlioblastomaHumansNeoplasm Recurrence, LocalTumor MicroenvironmentConceptsGBM tumorsTumor microenvironmentNeoplastic cellsResponse to standard treatmentTreatment resistance mechanismsDifferentiated neoplastic cellsSurrounding normal brainResponder subtypesGBM stem cellsAssociated with distinct changesRecurrent tumorsIDHwt glioblastomasTargeted therapyIDH1 mutationStandard treatmentBrain neoplasmsTumorCancer-cellBrain tumorsEffective treatmentNeurotransmitter signalingStem cellsMesenchymal transitionPairs of pre-SubtypesUtility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer.
Bansal V, Belmont E, Godley F, Dhiman A, Witmer H, Li S, Liao A, Eng O, Turaga K, Shergill A. Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer. Journal Of The American College Of Surgeons 2024, 238: 1013-1020. PMID: 38299640, DOI: 10.1097/xcs.0000000000001028.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerRecurrence siteOptimal resectionCtDNA detectionDistant recurrenceColorectal cancerClinical diagnosis of recurrenceDiagnosis of recurrenceDistant lymph nodesSingle-institution studyLevels of ctDNACtDNA assessmentCtDNA levelsDistant diseaseCtDNA testingPostoperative recurrenceRecurrent casesLymph nodesMonths postsurgeryDisease sitesResectionRecurrenceDNA assessmentPatientsCRC metastasis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply